SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes: Boston Wednesday, August 6, 2025, 13:00 Hrs [IST] SOPHiA GENETICS, a clo ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

Despite challenges in the biopharma sector, Sophia Genetics SA (SOPH) showcases robust growth and strategic advancements in ...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025.

Portfolio Receipts was $727 million in the second quarter of 2025, an increase of 20% compared to $608 million in the second quarter of 2024, primarily driven by the same Royalty Receipts increases ...

The study’s findings could influence AstraZeneca’s stock performance by providing valuable insights into treatment efficacy, potentially affecting investor sentiment. As the study progresses, it may ...

Market Implications: This study update could positively influence AstraZeneca’s stock performance and investor sentiment by showcasing the company’s commitment to advancing cancer treatments. As the ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

DelveInsight's CLK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.